|
|
 |
References
| 1. |
Bethel MA, Feinglos MN. Basal insulin therapy in type 2 diabetes. J Am Board Fam Pract. 2005;18(3):199-204.
|
| 2. |
ADA American Diabetes Association website. Sections: Type 2 Diabetes, Hypoglycemia, A1C. Available at http://www.diabetes.org. Accessed on June 14, 2006.
|
| 3. |
NovoLog® Mix 70/30 Prescribing Information.
|
| 4. |
Raskin P, Allen E, Hollander P, et al, for the INITIATE Study Group. Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28(2):260-265.
|
| 5. |
Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med. 2002;19:393-399.
|
| 6. |
Boehm BO, Vaz JA, Brøndsted L, Home PD. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med. 2004;15:496-502.
|
| 7. |
Niskanen L, Jensen LE, Råstam J, Nygaard-Pedersen L, Erichsen K, Vora JP. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther. 2004;26:531-540.
|
| 8. |
Korytkowski M, Bell D, Jacobsen C, Suwannasari R, for the FlexPen® Study Team. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25:2836-2848.
|
| 9. |
Garber AJ, Wahlen T, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab. 2006;8:58-66.
|
| 10. |
IMS Health, Inc. Q3 2005 IMS formulary focus data, interstudy lives. Valid as of December 2005.
|
| 11. |
Data on File. Novo Nordisk Inc, Princeton, NJ. |
|
|
